FDA NDC
Yorvipath
This name is from the loaded FDA file.
Source: FDA NDC Directory, live from openFDA. Publisher page
- NDC
- 73362-100
- Proprietary name
- Yorvipath
- Nonproprietary name
- Palopegteriparatide
- Labeler
- Ascendis Pharma, Endocrinology, Inc.
- Dosage form
- INJECTION, SOLUTION
- Strength
- 168 ug/.56mL
Run it in Rivvi
Which 2027 plans near you dropped or restricted Palopegteriparatide?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan, from the CMS Part D files.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.